AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-14 and is reviewed periodically as new material appears.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
In 2015, she was a laureate of the L'Oréal-UNESCO For Women in Science Awards "for her groundbreaking work in macromolecular mass spectrometry and pioneering gas phase structural biology by probing the structure and reactivity of single proteins and protein complexes, including membrane proteins." In 2017, she was elected a Foreign Associate of the US National Academy of Sciences. In 2018, she won the Frank H. Field and Joe L. Franklin Award for Outstanding Achievement in Mass Spectrometry from the American Chemical Society. In 2019, she won the Novozymes Prize for "almost single-handedly founding a subfield of mass spectrometry proteomics". Also in 2019 she received the Royal Medal. In 2020, she was chosen as the recipient of the Othmer Gold Medal. In 2021, she received the 2022 Louis-Jeantet Prize for Medicine. and the 2022 European Chemistry Gold Medal by the European Chemical Society. Also in 2021, she became an International Honorary Member of the American Academy of Arts and Sciences. In 2022, she was awarded the Franklin Institute Award for Chemistry. In 2023, she was elected to the American Philosophical Society and was awarded the John B. Fenn Award for Distinguished Contribution to Mass Spectrometry. She was named one of the top ten "Innovators and Trailbalzers" on the 2023 Power List by the Analytical Scientist. In 2024, she received the EPO European Inventor Lifetime Achievement Award for her work in mass spectrometry that significantly advanced biochemical research and medical diagnostics.
=== Pharmacogenetics and pharmacogenomics === Pharmacogenetics is defined as the study of inherited genes causing different drug metabolisms that vary from each other, such as the rate of metabolism and metabolites. Pharmacogenomics is defined as the study of associating the drug response with one's gene. Both terms are similar in nature, so they are used interchangeably. Multiple alleles can contribute together to a change in response to a drug by expressing a different form of an enzyme that responds differently than the normal ones. The different forms of enzymes (phenotypes) include ultra-rapid metabolizers, moderate metabolizers, no-enzyme activity, etc. The genetic variations can also be used to match the particular adverse drug reaction in order to prevent the patient from suffering the unfavorable outcomes. The genetic make-up can affect the pharmacokinetics.
Local chemical messengers, not generally considered part of the endocrine system, include autocrines, which act on the cells that secrete them, and paracrines, which act on a different cell type nearby. The ability of a target cell to respond to a hormone depends on the presence of receptors, within the cell or on its plasma membrane, to which the hormone can bind. Hormone receptors are dynamic structures. Changes in the number and sensitivity of hormone receptors may occur in response to high or low levels of stimulating hormones. Blood levels of hormones reflect a balance between secretion and degradation/excretion. The liver and kidneys are the major organs that degrade hormones; breakdown products are excreted in urine and faeces. Hormone half-life and duration of activity are limited and vary from hormone to hormone. Interaction of hormones at target cells Permissiveness is the situation in which a hormone cannot exert its full effects without the presence of another hormone. Synergism occurs when two or more hormones produce the same effects in a target cell and their results are amplified. Antagonism occurs when a hormone opposes or reverses the effect of another hormone.
Sources: en.wikipedia.org
=== Components === 44th Reconnaissance Squadron (Fighter), 1 July 1943 – 15 August 1943 45th Reconnaissance Squadron (Fighter), 1 July 1943 – 11 August 1943 46th Reconnaissance Squadron (Bomber), 1 July 1943 – 15 August 1943 47th Liaison Squadron, 1 July 1943 – 11 August 1943
=== Religious criticisms === Many Christians criticized the war. Robert McElroy, a Cardinal for the Catholic Church, called for an end for the war, and Leo XIV, the current Pope echoed this statement. Hegseth in response attempted to appeal to earlier times in the Catholic Church, particularly the era of the Crusades. However, the Crusaders were not only anti-Muslim but also anti-Jewish.
== References == Pathology Outline, Fallopian Tubes Ogawa K, Johansson SL, Cohen SM (October 1999). "Immunohistochemical analysis of uroplakins, urothelial specific proteins, in ovarian Brenner tumors, normal tissues, and benign and neoplastic lesions of the female genital tract". Am. J. Pathol. 155 (4): 1047–50. doi:10.1016/S0002-9440(10)65206-6. PMC 1867018. PMID 10514386. Wrong Diagnosis.com, Brenner tumors
The evidence for brain-derived neurotrophic factor (BDNF) in mediating some of the neurobiological effects of physical exercise was noted in one review which hypothesized that increased BDNF signaling is responsible for the antidepressant effect. A meta-analysis of 15 studies published in 2022 suggested a curvilinear dose-response relationship between exercise and depression risk, with low levels of exercise showing the best dose-response.
Sources: en.wikipedia.org
Each tissue returns to its equilibrium state after excitation by the independent relaxation processes of T1 (spin-lattice; that is, magnetization in the same direction as the static magnetic field) and T2 (spin–spin; transverse to the static magnetic field). To create a T1-weighted image, magnetization is allowed to recover before measuring the MR signal by changing the repetition time (TR). This image weighting is useful for assessing the cerebral cortex, identifying fatty tissue, characterizing focal liver lesions, and in general, obtaining morphological information, as well as for post-contrast imaging.
=== Sanctions === After the declaration of independence, and indeed for the entire duration of its existence, Rhodesia did not receive official recognition from any state, although it did maintain diplomatic relations with South Africa, which was then under apartheid. South Africa did not recognise Rhodesia to preserve its fragile positions with other nations, but frequently assisted the Rhodesian state. Portugal maintained informal relations until the Carnation Revolution of 1974. The day following the declaration of independence, the United Nations Security Council passed a resolution (S/RES/216) calling upon all states not to accord Rhodesia recognition, and to refrain from any assistance. The Security Council also imposed selective mandatory economic sanctions, which were later made comprehensive. The US, despite voting in favour of the sanctions at the UNSC, violated them to buy chromium ore from Rhodesia. Kenneth Kaunda, president of Zambia, also accused western oil companies of violating the sanctions and selling oil to Rhodesia.
==== MeSH D12.776.624.776.355 – cyclin-dependent kinase inhibitor proteins ==== MeSH D12.776.624.776.355.100 – cyclin-dependent kinase inhibitor p15 MeSH D12.776.624.776.355.200 – cyclin-dependent kinase inhibitor p16 MeSH D12.776.624.776.355.300 – cyclin-dependent kinase inhibitor p18 MeSH D12.776.624.776.355.400 – cyclin-dependent kinase inhibitor p19 MeSH D12.776.624.776.355.500 – cyclin-dependent kinase inhibitor p21 MeSH D12.776.624.776.355.600 – cyclin-dependent kinase inhibitor p27 MeSH D12.776.624.776.355.700 – cyclin-dependent kinase inhibitor p57
There are seven major structural groups, which are naphthoylindoles, naphthylmethylindoles, naphthoypyrroles, naphthylmethylindenes, phenylacetylindoles, cyclohexylphenols and classical cannabinoids respectively. Compared with classical cannabinoids, synthetic cannabinoids differ structurally. Some common synthetic cannabinoids are available in the market such as JWH-018, which is the most well-known naphthoylindole and JWH-250, a phenylacetylindole. They are sold under the brand name "Spice" as a recreational drug over the past decade.
== tRNAome == Transfer RNA (tRNA) is an important part of Translation. tRNAs read the mRNA, bringing the amino acids the ribosome assembles into a polypeptide. As such, the abundances and types of tRNAs hava a large effect on the speed of protein synthesis. tRNAs can be very similar to other tRNAs, with some tRNA species only differing by a single nucleotide. This, coupled with similar secondary and tertiary structures, makes separating different tRNA species difficult.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.